Patients with known human immunodeficiency virus (HIV) positive must have a cluster of differentiation (CD)4 cell count be >= 350 cells/mm^3 within 14 days prior to study entry (note, however, that HIV testing is not required for entry into this protocol)
Patients with active human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral treatment (HAART) is allowed
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy will be eligible unless the cluster of differentiation (CD)4 count is < 200 cells/mm^3 within one month of study enrollment
Human immunodeficiency virus (HIV)-positive patients who are not receiving: agents with the potential for PK interactions with romidepsin or hepatotoxic antiretrovirals (nucleoside reverse-transcriptase inhibitors [NRTIs]: abacavir, didanosine, emtricitabine, lamivudine, stavudine, and zidovudine), dual protease inhibitor (PI)-based regimens except low-dose boosting with ritonavir, atazanavir, indinavir, maraviroc, and nevirapine may be eligible; additionally, the HIV-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3; if the specific cause of hepatic dysfunction is unknown, the patient should be worked up for other viral causes of hepatitis and their eligibility determined after consultation with the principal investigator
Patients with human immunodeficiency virus (HIV) who are not receiving cytochrome p450 inhibitors, and who have a minimum of 300+ CD4+ cells/mm^3, an undetectable viral load, and no history of acquired immune deficiency syndrome (AIDS) indicator conditions
HIV-positive patients on combination antiretroviral therapy which include cytochrome p450 inhibitors are ineligible; patients with CD4 counts less than 300 CD4+ cells/mm^3 and or a high viral load are ineligible
Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:* Cluster of differentiation (CD)4 cells >= 500/mm^3* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART* No zidovudine or stavudine as part of cART* Patients who are HIV+ and do not meet all of these criteria are not eligible for this study
Human immunodeficiency virus (HIV) positive with CD4 count < (350) cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= (350) cells/microliter, and no known detectable viral load, at the time of study entry; note also that HIV testing is not required for eligibility for this protocol
STEP I: Human immunodeficiency virus (HIV) infection is not excluded; known HIV positive patients must meet the following criteria:* Cluster of differentiation (CD)4 cell count >= 350/mm^3* No history of acquired immune deficiency syndrome (AIDS)-related illness* Not currently prescribed zidovudine or stavudine
A cluster of differentiation (CD)4+ lymphocyte count > 50/mcL will be required within 2 weeks of study participation
RANDOMIZED PHASE II (ARMS K AND L): HIV positive patients are eligible provided they meet the other protocol criteria including the following:* Long term survival expected were it not for the cHL* HIV viral loads undetectable by standard clinical HIV testing* Willing to adhere to effective combination antiretroviral therapy
Patients with human immunodeficiency virus (HIV) are eligible if they are not on antiviral agents and have adequate cluster of differentiation (CD)4 counts (>= 500 mm^3)
Patients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:* CD4+ cells >= 350/mm^3 (nadir)* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART* No zidovudine or stavudine as part of cARTPatients who are HIV+ and do not meet all of these criteria are not eligible for this study
Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following:* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness* Cluster of differentiation (CD)4+ cells nadirs > 350/mm^3 within 28 days prior to registration* Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3 within 28 days prior to registration* Note: HIV+ patients who enroll on this study and are assigned to treatment with ixazomib may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4
Human immunodeficiency virus (HIV)-positive patients on antiviral drugs and/or cluster of differentiation (CD)4 count is inadequate (< 500); if neither condition exists, HIV-positive patients are eligible
Disease must be cluster of differentiation (CD)30 positive
Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:* No history of acquired immune deficiency syndrome (AIDS)-related complications other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia* Patient must have serum HIV viral load of < 200 copies/mm^3* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy* Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat, stavudine, or on regimens containing stavudine or zidovudine* It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir, combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine
Cluster of differentiation (CD)4 count >= 200 within 120 days prior to enrollment or plasma HIV-1 RNA < 200 copies/mL within 120 days prior to randomization
Patients with known human immunodeficiency virus (HIV) infection are eligible if not on antiviral agents and cluster of differentiation (CD)4 counts are adequate (>= 500)
Patients with a known history of human immunodeficiency virus (HIV) seropositivity:* Must have undetectable viral load using standard HIV assays in clinical practice* Must have cluster of differentiation (CD)4 count >= 400/mcL* Must not require prophylaxis for any opportunistic infections (i.e., fungal, Mycobacterium avium complex [mAC], or pneumocystis jiroveci pneumonia [PCP] prophylaxis)* Must not be newly diagnosed within 12 months prior to sub-study registration
Patients known to be human immunodeficiency virus (HIV) positive with one or more of the following:* Baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3* History of acquired immune deficiency syndrome (AIDS) indicator conditions* Anti-retroviral therapy with any potent CYP3A4 inhibitor
Severe, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration* Transmural myocardial infarction within the last 6 months prior to registration* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD) 4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol* End-stage renal disease (i.e., on dialysis or dialysis has been recommended)
Known human immunodeficiency virus (HIV)-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3
Severe, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol* End-stage renal disease (i.e., on dialysis or dialysis has been recommended)
Patients known to be positive for HIV (the human immunodeficiency virus) may be eligible, providing they meet the following additional criteria within 28 days prior to registration:* No history of acquired immune deficiency syndrome (AIDS)-defining conditions* CD4 cells > 350 cells/mm^3* If on antiretroviral agents, must not include zidovudine or stavudine* Viral load =< 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or =< 25,000 copies HIV mRNA/mm^3 if not on cART* Highly active antiretroviral therapy (HAART) regimens are acceptable providing they have only weak P450A4 interactions
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; if an HIV-positive patient has adequate cluster of differentiation (CD4) counts (CD4 above the lower limit of institutional normal) and is on antiretroviral therapy with newer agents, which are not strong cytochrome (CYP) inhibitors, they will be eligible
Patients with known human immunodeficiency virus (HIV) may be eligible providing they meet the following additional criteria:* Cluster of differentiation (CD)4 cells >= 500/uL* Serum HIV viral load of < 25,000 IU/ml* No current antiretroviral therapy** Tests must be obtained within 28 days prior to registration; patients who are HIV positive (+) and do not meet all of these criteria are not eligible for this study (HIV/hepatitis testing are not required for patients without known infection)
Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol
Patients who are human immunodeficiency virus (HIV) positive may participate if they meet the following eligibility requirements:* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective* They must have a cluster of differentiation (CD)4 count of greater than 250 cells/mcL* They must not be receiving prophylactic therapy for an opportunistic infection
Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), cluster of differentiation (CD)4 counts are greater than 350 and viral load is undetectable
In order for patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) to be eligible, they must be on a stable highly active antiretroviral therapy (HAART) regimen, have cluster of differentiation (CD)4 counts > 350, with no detectable viral load on quantitative polymerase chain reaction (PCR)
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible provided that they meet the following criteria in addition to the other protocol criteria: * Cancer as the only acquired immunodeficiency syndrome (AIDS)-defining condition* Cluster of differentiation (CD)4 cell count >= 250* Treatment sensitive HIV and prospects for long term survival on the basis of HIV disease alone* Willing to take anti-HIV therapy that will have minimal potential for pharmacokinetic interactions with GDC-0449
Severe, active co-morbidity defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration* Chronic obstructive pulmonary disease exacerbation or other acute respiratory illness precluding study therapy at the time of registration* Severe hepatic disease defined as a diagnosis of Child-Pugh class B or C hepatic disease* Renal tubular acidosis or metabolic acidosis* Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; Note also that HIV testing is not required for eligibility for this protocol
If HIV-positive, any cluster of differentiation (CD)4 count will be allowed on study
Patients who are human immunodeficiency virus (HIV)-positive are eligible if: * CD4+ cell count greater or equal to 250 cells/mm^3* If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; for experimental cancer therapeutics with CYP3A/4 interactions, protease inhibitor therapy is disallowed; suggested regimens to replace protease inhibitor therapy include dolutegravir given with tenofovir/emtricitabine; raltegravir given with tenofovir and emtricitabine; once daily combinations that use pharmacologic boosters may not be used* No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts* Probable long-term survival with HIV if cancer were not present
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV patients treated with regimens that have low cytochrome P450 (CYP450) inhibition may be allowed as long as the patient�s general health and cluster of differentiation (CD)4 counts are within acceptable levels
Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions
Human immunodeficiency virus (HIV)-positive patients on antiretroviral medications that are CYP3A4 substrates will be closely monitored; HIV-positive patients will be excluded if they have a cluster of differentiation 4 (CD4) count < 200
Human immunodeficiency virus (HIV)-infected persons are eligible if they meet other eligibility criteria including the following:* No prior acquired immune deficiency syndrome (AIDS)-defining condition other than cluster of differentiation (CD)4+ cells nadir < 200/mm^3* Pre-leukemia CD4+ cell count >= 250/mm^3* Willing to adhere to antiretroviral therapy regimen with minimal overlapping toxicity and PK interactions with the experimental agents in this study; no zidovudine- and no ritonavir-containing regimens and no 3-drugs-in-1 pill regimens containing pharmacologic boosters are allowed; recommended regimens are integrase inhibitors combined with tenofovir and emtricitabine
Human immunodeficiency virus (HIV) positive (+) patients with cluster of differentiation 4 (CD4) counts >= 250 cells/mm^3 on anti-viral therapy
Human immunodeficiency (HIV) positive (+) patients are eligible provided they meet the other eligibility criteria and:* Cluster of differentiation (CD)4+ cells are >= 250/mm^3* There is no history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ cell count* The following antiretroviral agents are not allowed: zidovudine, stavudine, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, combination pills with pharmacologic boosters* Recommended antiretroviral regimens to avoid pharmacokinetic (PK) interactions include strand integrase inhibitors with nucleoside reverse transcriptase inhibitors (for example, dolutegravir given with tenofovir and emtricitabine)
Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all other eligibility criteria, and:* There is no prior history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ T-cell count or B-cell lymphoma* In the opinion of an expert in HIV disease, prospects for long-term survival are excellent were it not for the diagnosis of lymphoma* Use of HIV protease inhibitors as part of the anti-HIV regimen OR as a pharmacologic booster is not allowed* Zidovudine is not allowed* Once daily combination pills for HIV containing a pharmacologic booster such as cobicistat are not allowed* Patients with multi-drug resistant HIV are not eligible
Human immunodeficiency virus (HIV) infected patients (if HIV positive)* HIV infected individuals are eligible provided they meet all the protocol eligibility criteria in addition to the following:** No history of acquired immune deficiency syndrome (AIDS) defining illness other than a historic CD4+ T-cell nadir < 200/mm^3** Prior to leukemia diagnosis, the HIV disease was uncomplicated as evidenced by:*** The CD4+ T-cell counts were generally in excess of 300/mm^3*** The HIV viral loads were less than 200 copies/ml if on anti-HIV therapy*** If the HIV is newly diagnosed or there is no history of using anti-HIV therapy, there are no AIDS defining conditions or other HIV-related symptoms*** Zidovudine is not allowed as part of the anti-HIV therapy
Severe, active comorbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration* Uncontrolled, clinically significant cardiac arrhythmias* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter** Note: patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to Step 1 registration** Note: HIV testing is not required for eligibility for this protocol
Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all the other eligibility criteria of the study in addition to the following: * No history of acquired immune deficiency syndrome (AIDS)-defining conditions other than lymphoma or history of CD4+ T-cells below 200/mm^3 prior to beginning combination antiretroviral therapy (cART)* After HIV diagnosis and during treatment with cART, patients should have maintained CD4+ T-cells >= 350/mm^3 prior to lymphoma diagnosis; patients who never immune reconstituted to a stable level above 350/mm^3 are not eligible* At time of study entry CD4+ T-cells must have recovered from prior lymphoma therapy to >= 250/mm^3* At the time of study entry the HIV viral load must be undetectable by standard laboratory assay * During prior lymphoma therapy, patients must not have experienced documented infections attributed to the HIV+ status* No history of non-adherence to cART and willing to adhere to cART while on study* Antiretroviral drugs with overlapping or similar toxicity profiles as study agents not allowed:** Efavirenz not allowed** Stavudine not allowed** Zidovudine not allowed* Patients must be willing to be followed at a minimum of approximately every 3 months by physician expert in HIV disease management
Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible; patients with poorly controlled HIV are not eligible
Human immunodeficiency virus (HIV)+ patients are eligible for the trial provided they meet the other study criteria in addition to the following:* CD4+ T-cells >= 250/mm^3* HIV sensitive to antiretroviral therapy* Zidovudine not allowed* Long term survival anticipated on the basis of HIV alone were it not for the lymphoma* No concurrent acquired immunodeficiency syndrome (AIDS)-defining illness other than the lymphoma
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible; unless the patient�s cluster of differentiation (CD)4+ count is below the institutional lower limit of normal
Healthy human immunodeficiency virus (HIV)-infected patients are eligible, provided that they meet all the other study criteria in addition to the following (HIV testing is not required for study enrollment):* CD4+ cell count >= 250/mm^3* HIV viral loads undetectable by standard clinical tests
Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 (e.g. regimens containing ritonavir, cobicistat, efavirenz or etravirine) are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible; patients with poorly controlled HIV are not eligible
Patients with a known history of human immunodeficiency virus (HIV) are eligible, if they meet all of the following conditions:* No history of HIV complications with the exception of cluster of differentiation (CD)4 count < 200 cells/mm^3* No antiretroviral therapy with overlapping toxicity such as myelosuppression* HIV viral loads below the limit of detection* No history of highly active antiretroviral therapy (HAART)-resistant HIV
Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease must:* Have a cluster of differentiation (CD)4 count >= 200 cells/uL within 30 days before beginning study therapy* Be off all antiretroviral therapy (prophylaxis/treatment) more than 60 days before beginning study therapy, and* Have no evidence of opportunistic infections
Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate CD4 counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients must be on a stable anti-viral therapy
Human immunodeficiency virus (HIV)-positive patients are eligible provided the following criteria are met: CD4 count > 350/mm^3, an undetectable viral load, and not receiving prophylaxis antibiotics
Known human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol; this exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
Human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to step 1 registration; note also that HIV testing is not required for eligibility for this protocol
Patients who are known to be human immunodeficiency virus (HIV)-positive at registration are eligible at the time of registration:1. Cluster of differentiation (CD)4+ cell count greater or equal to 250 cells/mm^32. If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; once daily combinations that use pharmacologic boosters may not be used3. No history of non-malignancy acquired immunodeficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts
Patients with a known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) will be eligible if:* They are generally healthy from an HIV perspective and on a stable anti-retroviral regimen for > 6 months* They have had no AIDS-defining conditions in the past 12 months other than historically low CD4+ cell counts* They have an undetectable viral load on standard assays
Human immunodeficiency virus (HIV) positive patients are not excluded, but to enroll, must meet all of the below criteria:* HIV is sensitive to antiretroviral therapy* Must be willing to take effective antiretroviral therapy that has minimal overlapping toxicity and pharmacokinetic interactions with protocol therapy* No history of HIV-related opportunistic disease or acquired immune deficiency syndrome (AIDS)-defining conditions within past 12 months other than historic CD4+ T-cell counts below 200 cells/mm^3* Expected long-term survival if lymphoma were not present
Major medical illnesses or psychiatric impairments, which in the investigators opinion, will prevent administration or completion of the protocol therapy and/or preclude informed consent; these include, but are not restricted to:* Unstable angina and/or congestive heart failure requiring hospitalization at the time of step 2 registration* Transmural myocardial infarction within the last 6 months prior to step 2 registration* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step 2 registration* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step 2 registration* Type II neurofibromatosis (NF2)* Ailments entailing substantial increases in sensitivity and side effect risk from radiation therapy (ataxia telangiectasia, Nijmegen breakage syndrome, and human immunodeficiency virus (HIV) with CD4 count < 200 cells/microliter); HIV testing is not required for eligibility for this protocol, and known HIV positive patients are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to step 2 registration* Inability to undergo MRI with and without contrast (e.g. claustrophobia, non-MRI compatible implant or foreign body, etc) or receive gadolinium; note that patients with severe claustrophobia are permitted on this study if they are willing and able to undergo MRI with adequate sedation or anesthesia
Severe, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months* Transmural myocardial infarction within the last 6 months* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step 1 registration* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step 1 registration* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol* End-stage renal disease (ie, on dialysis or dialysis has been recommended)
Human immunodeficiency virus (HIV) positive (+) patients with CD4 counts >= 250 cells/mm^3 on anti-viral therapy are eligible for the study
HIV positive with CD4 count < 200 cells/microliter; note that patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter prior to registration; note also that HIV testing is not required for eligibility for this protocol
Patients with hepatitis B virus infection must have undetectable hepatitis B virus (HBV) on suppressive therapy and no evidence of HBV-related hepatic damage; patients with hepatitis C virus infection are eligible if complete eradication therapy has been successfully completed, and there is no detectable hepatitis C virus (HVC) or related hepatic damage; patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:* Patient must have no history of acquired immune deficiency syndrome (AIDS)-related complications, other than a history of low CD4+ T-cell count (< 200/mm3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia* Patient must have serum HIV viral load of < 200 copies/mm^3* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy; (recommend a regimen of the integrase inhibitor dolutegravir combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine)* Protease inhibitors and once daily formulations containing cobicistat are NOT allowed* Stavudine and zidovudine (AZT) are NOT allowed